PTC Therapeutics (PTCT) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

PTCT PTC Therapeutics

Watchlist

43.840
+0.760+1.76%

Close Jan 17 16:00 ET

43.870
+0.030+0.07%

Post 16:35 ET

3.38BMarket Cap-7.38P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

PTC to Announce Fiscal Q1'25 Results on Wednesday, February 5th, 2025
PR NewswireJan 15 09:49 ET
Cantor Fitzgerald Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $76
Moomoo NewsJan 15 08:31 ET · Ratings
Cantor Fitzgerald Sticks to Its Buy Rating for PTC Therapeutics (PTCT)
TipRanksJan 15 08:18 ET · Ratings
PTC Therapeutics Price Target Lowered at Cantor Fitzgerald, a Top Pick in 2025
TipRanksJan 15 08:06 ET
Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Lowers Price Target to $76
BenzingaJan 15 07:48 ET · Ratings
PTC Therapeutics Analyst Ratings
BenzingaJan 15 07:46 ET · Ratings

Comments

Lnova

Dec 19, 2024 17:24

$PTC Therapeutics (PTCT.US)$
PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia
12/19/2024 08:00AM ET
- If approved, vatiquinone would be the first and only authorized therapy for children with FA -
- PTC's fourth approval application submitted to FDA in 2024 -
WARREN, N.J., Dec. 19, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today the submission of the vatiquinone New Drug Application (NDA) ...

Meltyy

May 22, 2024 02:52

Biotech Stock Catalyst Watchlist 👀

🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...

mad541

May 20, 2024 07:38

$PTC Therapeutics (PTCT.US)$ just dud offering 22.87 a share get out 🔻🔻🔻🔻

Moomoo AI

Mar 3, 2024 08:56

PTC Therapeutics' low P/S ratio is seen as reasonable due to industry underperformance. However, weak revenue outlook is pressuring shares, making maintaining current prices challenging. Shareholders accept the low P/S, expecting no future revenue surprises.

There's No Escaping PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Muted Revenues Despite A 27% Share Price Rise

Moomoo AI

Feb 14, 2024 08:26

Recent insider selling at PTC Therapeutics outweighs insider buying, a potential bearish sign. Despite some insider buying, the long-term outlook lacks positivity. Insider ownership suggests alignment with shareholders, but insider selling warrants caution.

PTC Therapeutics Insiders Sold US$1.1m Of Shares Suggesting Hesitancy

Heat List

Overall

No Data